Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
about
Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.Challenges in translating endpoints from trials to observational cohort studies in oncologyAromatase inhibitors in the treatment of endometriosisAromatase inhibitors for the treatment of endometriosisGuidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Exemestane for breast cancer prevention: a critical shift?Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.Management of aromatase inhibitor-induced arthralgia.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivorsVariation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.The evolving role of zoledronic acid in early breast cancerPotential role of aromatase inhibitors in the treatment of endometriosisRisk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.Letrozole therapy alone or in sequence with tamoxifen in women with breast cancerIs Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioEndocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine?Adjuvant Endocrine Therapy in Premenopausal PatientsAdjuvant Endocrine Therapy in Early Postmenopausal Breast CancerThe multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancerA prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapyCost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.Musculoskeletal adverse events associated with adjuvant aromatase inhibitors.Adverse effects of azacitidine: onset, duration, and treatment.Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Is Chemoendocrine Treatment without Alternative?Patterns of bone density evaluation in a community population treated with aromatase inhibitors.Preventative therapies for healthy women at high risk of breast cancer.Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associationsGenome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.Adverse effects of endocrine therapy in breast cancer: single institute experience.The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumThe science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumorsEvaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyEffects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trialAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
P2860
Q25257781-BCBD5E64-EDF6-45E5-90D0-2C074984C3FBQ26746190-41CDF3B2-5BE9-47EB-B4A9-F0E0C71484BFQ26751946-10602B76-9CD1-43BF-88BF-9AECF85E0E27Q27010275-35A4B38B-CDD9-4522-A369-D787EC436909Q27027579-90AA3D9F-2F84-42E0-9136-8E4C50C6005EQ27028211-221E8D44-6122-4A6E-9A73-A0C82D59D98BQ33572119-C50DDC3A-E214-4CA4-B1AD-8D6AF08327C7Q33631047-9989B2B3-B8DA-470C-98F6-87D3FC042920Q33647466-61B99B18-D79E-4134-A0F0-416586272FA0Q33680411-4A3B4C07-7CA8-405E-8630-0D743C8232E3Q33698446-F27B4A98-E510-40EC-9013-669540FE5201Q33714141-550739D4-0E96-4D43-B49E-E43D1ED096E6Q33793932-FC07B641-A1DC-44EE-B05A-A5491F9E6AD3Q33915978-E88F6137-6167-4D8B-8A3B-882FEC159B2FQ33961506-01CB389C-F443-415C-8EB8-132317345552Q34007066-67622CA2-470F-4475-B762-7FB367CB500BQ34059713-B47D716F-23A4-4A5E-A792-75976DF608BBQ34066531-5F79D4CA-A71D-46E8-94A8-53979470B574Q34095816-A578687D-5F4E-4963-A261-8BAE57719416Q34095945-DFA5986A-CD2C-4774-8A81-1FA0F48F762EQ34096277-84C06A15-310B-4A65-AB08-0F3953AB29A6Q34096283-1F6AA995-F556-4AD0-9ADA-71BD72650BBEQ34113489-61BDC501-2664-4846-912C-0391BAB10ACEQ34116012-45E53ACD-BBE2-44EF-AA36-E2EA9B60E0F0Q34134780-DC2F5BDF-98AA-4BA4-BA20-AA24D5D795A3Q34140072-D491F37C-3B81-405A-8378-2789C662BF3AQ34143532-7C9AE37A-0281-4BAD-BD48-615148021C07Q34193934-9BA5FCBB-76A1-4A0B-9D5A-74642A19C0DDQ34233815-5E42E670-859B-468E-BD86-921505BCE87FQ34284263-2E4109DE-4A27-46BA-9CA2-B2A944FF3DD8Q34335213-020A4BCF-0879-4C35-A687-A2BF9A906781Q34393592-F1A8C675-5C81-4669-AB38-A5F2CC9D5FFEQ34423538-8B379996-56AD-414F-A0B2-DB8F76DDAD91Q34488758-D520FDC3-9A93-4E63-951B-58BCEA37CA4DQ34589107-1C21BD91-015E-4BF5-8BB0-7164BC9B089DQ34592879-B39B173D-C472-40B1-8548-C6D515F5EF52Q34617864-BB7D3949-BF2B-4B94-B97F-E8A177DB0ECCQ34764981-24056623-E827-4627-8579-D9B253839177Q34765951-976AC778-2A5C-45B1-B507-770CDDC7C4E5Q34877463-613FCCD8-CCDD-4F01-910A-8995885E2ABF
P2860
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@ast
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@en
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@nl
type
label
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@ast
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@en
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@nl
prefLabel
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@ast
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@en
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@nl
P2093
P1433
P1476
Switching of postmenopausal wo ...... CSG trial 8 and ARNO 95 trial.
@en
P2093
ABCSG and the GABG
Christian Menzel
Christoph Tausch
Guenther Gademann
Hellmut Samonigg
Joern Hilfrich
Johann Wolfgang
Manfred Kaufmann
Martina Mittlboeck
Michael Gnant
P304
P356
10.1016/S0140-6736(05)67059-6
P407
P50
P577
2005-08-01T00:00:00Z